Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial-Reference-Cited by-同舟云学术

Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial

Published:2023-09 Issue:3 Volume:89 Page:486-495
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Strober Bruce,Paul Carle,Blauvelt Andrew,Thaçi Diamant,Puig Luis,Lebwohl Mark,White Katy,Vanvoorden Veerle,Deherder Delphine,Gomez Natalie Nunez,Eyerich Kilian

Funder

UCB Pharma

UCB Pharma GmbH

Publisher

Elsevier BV

Subject

Dermatology

Reference34 articles.

1. Interleukin-17 cytokines: effectors and targets in a psoriasis-A breakthrough in understanding and treatment;Prinz;J Exp Med,2020

2. Basic biology and role of interleukin-17 in immunity and inflammation;Zenobia;Periodontol 2000,2015

3. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis;Blauvelt;Clin Rev Allergy Immunol,2018

4. β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis;Kolbinger;J Allergy Clin Immunol,2017

5. Psoriasis pathogenesis and treatment;Rendon;Int J Mol Sci,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Short-term risk and long-term incidence rate of infection and malignancy with IL-17 and IL-23 inhibitors in adult patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis;Frontiers in Immunology;2023-11-29

2. Bimekizumab for the treatment of psoriatic arthritis;Expert Review of Clinical Immunology;2023-11-07

3. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation;Expert Opinion on Drug Safety;2023-05-04